SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Min Huang · Study

Home/Author

Min Huang

7 works· latest 2022· 3 institutionscluster: provisionalORCID 0000-0003-1960-4552

h-index7

i107

Citations497

Works here7

16

17

18

19

22

Most cited in this library

Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States2017 · 142 citations
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations2019 · 94 citations
Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France2018 · 72 citations
Cost–Effectiveness of Pembrolizumab Versus Chemotherapy as First-Line Treatment in PD-L1-Positive Advanced Non-Small-Cell Lung Cancer in the USA2019 · 68 citations
Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States2016 · 57 citations

Works

7 shown

The top 100 most cited articles on triple-negative breast cancer: a bibliometric analysis

Clinical and Experimental Medicine·2022·8 authors·review

15citations

Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review

PharmacoEconomics·2022·7 authors·review·Open access

49citations

Cost–Effectiveness of Pembrolizumab Versus Chemotherapy as First-Line Treatment in PD-L1-Positive Advanced Non-Small-Cell Lung Cancer in the USA

Immunotherapy·2019·7 authors·Open access

68citations

Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations

PharmacoEconomics·2019·6 authors·Open access

94citations

Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France

Lung Cancer·2018·7 authors·Open access

72citations

Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States

PharmacoEconomics·2017·6 authors·Open access

142citations

Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States

Journal of Medical Economics·2016·6 authors·Open access

57citations